• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症风险外显率荟萃分析中确定偏倚的校正

Adjusting for Ascertainment Bias in Meta-Analysis of Penetrance for Cancer Risk.

作者信息

Ruberu Thanthirige Lakshika M, Braun Danielle, Parmigiani Giovanni, Biswas Swati

机构信息

Department of Mathematical Sciences, University of Texas at Dallas, Richardson, Texas, USA.

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

出版信息

Stat Med. 2025 Feb 10;44(3-4):e10323. doi: 10.1002/sim.10323.

DOI:10.1002/sim.10323
PMID:39865362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11881752/
Abstract

Multi-gene panel testing allows efficient detection of pathogenic variants in cancer susceptibility genes including moderate-risk genes such as ATM and PALB2. A growing number of studies examine the risk of breast cancer (BC) conferred by pathogenic variants of these genes. A meta-analysis combining the reported risk estimates can provide an overall estimate of age-specific risk of developing BC, that is, penetrance for a gene. However, estimates reported by case-control studies often suffer from ascertainment bias. Currently, there is no method available to adjust for such bias in this setting. We consider a Bayesian random effect meta-analysis method that can synthesize different types of risk measures and extend it to incorporate studies with ascertainment bias. This is achieved by introducing a bias term in the model and assigning appropriate priors. We validate the method through a simulation study and apply it to estimate BC penetrance for carriers of pathogenic variants in the ATM and PALB2 genes. Our simulations show that the proposed method results in more accurate and precise penetrance estimates compared to when no adjustment is made for ascertainment bias or when such biased studies are discarded from the analysis. The overall estimated BC risk for individuals with pathogenic variants are (1) 5.77% (3.22%-9.67%) by age 50 and 26.13% (20.31%-32.94%) by age 80 for ATM; (2) 12.99% (6.48%-22.23%) by age 50, and 44.69% (34.40%-55.80%) by age 80 for PALB2. The proposed method allows meta-analyses to include studies with ascertainment bias, resulting in inclusion of more studies and thereby more accurate estimates.

摘要

多基因panel检测能够有效检测癌症易感基因中的致病变异,包括ATM和PALB2等中度风险基因。越来越多的研究探讨了这些基因的致病变异所赋予的乳腺癌(BC)风险。一项综合报告的风险估计值的荟萃分析可以提供特定年龄患BC风险的总体估计,即一个基因的外显率。然而,病例对照研究报告的估计值往往存在确诊偏倚。目前,在这种情况下没有可用的方法来校正这种偏倚。我们考虑一种贝叶斯随机效应荟萃分析方法,该方法可以综合不同类型的风险测量,并将其扩展以纳入存在确诊偏倚的研究。这是通过在模型中引入一个偏倚项并赋予适当的先验分布来实现的。我们通过模拟研究验证了该方法,并将其应用于估计ATM和PALB2基因致病变异携带者的BC外显率。我们的模拟表明,如果不校正确诊偏倚或在分析中舍弃存在这种偏倚的研究,与这些情况相比,所提出的方法能得出更准确和精确的外显率估计值。ATM基因致病变异个体的总体估计BC风险为:50岁时为5.77%(3.22%-9.67%),80岁时为26.13%(20.31%-32.94%);PALB2基因致病变异个体的总体估计BC风险为:50岁时为12.99%(6.48%-22.23%),80岁时为44.69%(34.40%-55.80%)。所提出的方法允许荟萃分析纳入存在确诊偏倚的研究,从而纳入更多研究,进而得到更准确的估计值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f38/11881752/080063f2cf84/nihms-2045783-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f38/11881752/169a12bbf1ae/nihms-2045783-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f38/11881752/080063f2cf84/nihms-2045783-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f38/11881752/169a12bbf1ae/nihms-2045783-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f38/11881752/080063f2cf84/nihms-2045783-f0002.jpg

相似文献

1
Adjusting for Ascertainment Bias in Meta-Analysis of Penetrance for Cancer Risk.癌症风险外显率荟萃分析中确定偏倚的校正
Stat Med. 2025 Feb 10;44(3-4):e10323. doi: 10.1002/sim.10323.
2
Penetrance of male breast cancer susceptibility genes: a systematic review.男性乳腺癌易感性基因的外显率:系统评价。
Breast Cancer Res Treat. 2022 Jan;191(1):31-38. doi: 10.1007/s10549-021-06413-2. Epub 2021 Oct 13.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
6
Behavioural interventions for smoking cessation: an overview and network meta-analysis.行为干预戒烟:综述和网络荟萃分析。
Cochrane Database Syst Rev. 2021 Jan 4;1(1):CD013229. doi: 10.1002/14651858.CD013229.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
9
Selenium for preventing cancer.硒预防癌症。
Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

本文引用的文献

1
Rejoinder to the discussion on "Bayesian meta-analysis of penetrance for cancer risk".对“癌症风险外显率的贝叶斯荟萃分析”讨论的回应。
Biometrics. 2024 Mar 27;80(2). doi: 10.1093/biomtc/ujae040.
2
Bayesian meta-analysis of penetrance for cancer risk.贝叶斯荟萃分析癌症风险外显率。
Biometrics. 2024 Mar 27;80(2). doi: 10.1093/biomtc/ujae038.
3
Meta-analysis of breast cancer risk for individuals with PALB2 pathogenic variants.PALB2 种系致病性变异个体的乳腺癌发病风险的荟萃分析。
Genet Epidemiol. 2024 Dec;48(8):448-454. doi: 10.1002/gepi.22561. Epub 2024 Apr 23.
4
Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients.芬兰患者乳腺癌风险基因中的致病变异谱
Cancers (Basel). 2022 Dec 14;14(24):6158. doi: 10.3390/cancers14246158.
5
Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations.加纳携带罕见种系致病性突变的女性的乳腺癌风险。
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1593-1601. doi: 10.1158/1055-9965.EPI-21-1397.
6
Evaluating breast cancer predisposition genes in women of African ancestry.评估非洲裔裔妇女的乳腺癌易感基因。
Genet Med. 2022 Jul;24(7):1468-1475. doi: 10.1016/j.gim.2022.03.015. Epub 2022 Apr 8.
7
Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil.巴西东北部癌症风险诊所中确诊的女性乳腺癌易感基因的突变谱。
Breast Cancer Res Treat. 2022 Jun;193(2):485-494. doi: 10.1007/s10549-022-06560-0. Epub 2022 Mar 30.
8
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.基于女性种系多基因测序结果得出的乳腺癌和卵巢癌外显率估计值。
JCO Precis Oncol. 2017 Nov;1:1-12. doi: 10.1200/PO.16.00066.
9
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.乳腺癌风险基因 - 超过 113000 名女性的关联分析。
N Engl J Med. 2021 Feb 4;384(5):428-439. doi: 10.1056/NEJMoa1913948. Epub 2021 Jan 20.
10
A Population-Based Study of Genes Previously Implicated in Breast Cancer.基于人群的先前与乳腺癌相关的基因研究。
N Engl J Med. 2021 Feb 4;384(5):440-451. doi: 10.1056/NEJMoa2005936. Epub 2021 Jan 20.